Among the first prognostic scores to be developed was the hepatoma arterial embolization prognostic (HAP) score, which is based on a simple points system involving tumor size, alpha‐fetoprotein (AFP), bilirubin, and albumin.13 The HAP score (which was enhanced by Kim et al.14 by adding tumor number [referred to as the modified HAP‐II {mHAP‐II}]) has the advantage of easy applicability and simplicity but does not permit individual patient‐level prognostication. The gene discussed is AFP; the disease is hepatocellular carcinoma.